BRIEF-AstraZeneca Says Calquence Met Primary Endpoint Against Ibrutinib

AstraZeneca PLC: * ASTRAZENECA PLC - CALQUENCE MET PRIMARY ENDPOINT AGAINST IBRUTINIB

ASTRAZENECA - CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA * ASTRAZENECA - SUPERIOR SAFETY ON KEY SECONDARY ENDPOINT OF ATRIAL FIBRILLATION Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)